Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference

Company Overview - Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development, production, and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx® plant cell-based protein expression system [4] - The company is notable for being the first to receive FDA approval for a protein produced through a plant cell-based suspension expression system [4] - Protalix has licensed worldwide development and commercialization rights for taliglucerase alfa, its first product, to Pfizer Inc., while retaining full rights in Brazil [4] Recent Developments - Protalix will present at the 2025 BIO CEO & Investor Conference on February 11, 2025, at 10:15 AM EST [1][2] - The company will provide a corporate overview and participate in one-on-one meetings with registered investors during the conference [2][3] - Protalix's second product, Elfabrio®, received approval from both the FDA and the European Medicines Agency in May 2023 [4] Product Pipeline - Protalix's development pipeline includes proprietary versions of recombinant therapeutic proteins targeting established pharmaceutical markets [5] - Key product candidates include PRX–115, a plant cell-expressed recombinant PEGylated uricase for uncontrolled gout, and PRX–119, a plant cell-expressed long-action DNase I for NETs-related diseases [5]